CAR-T cell therapy for non-Hodgkin lymphomas: A new treatment paradigm

LaQuisa Hill; Premal Lulla; Helen E Heslop

首页> 外文期刊>Advances in cell and gene therapy. >CAR-T cell therapy for non-Hodgkin lymphomas: A new treatment paradigm

【24h】

CAR-T cell therapy for non-Hodgkin lymphomas: A new treatment paradigm

机译：非霍奇金淋巴瘤的CAR-T细胞疗法：一种新的治疗范式

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The majority of patients with B-cell non-Hodgkin lymphoma (NHL) can be cured with standard chemoimmunotherapy. However, patients who fail first line therapy have dismal outcomes, particularly if they have disease that is resistant to salvage therapy, including chemoimmunotherapy, radiation and/or autologous stem cell transplantation. Indolent B-NHLs, such as follicular lymphoma (FL), although not generally considered curable may be treated over many years with good prognosis. However, a subset of indolent B-NHLs can undergo histologic transformation into more aggressive subtypes with outcomes similar to aggressive B-NHLs. In recent years, T cells, genetically modified with chimeric antigen receptors, have demonstrated a remarkable capacity to induce complete and durable clinical responses in patients with chemotherapy-refractory lymphomas. Indeed, two autologous CD19-directed CAR-modified T-cell products have now been FDA-approved for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma and transformed FL, while a plethora of other CAR-T cell targets are being explored in ongoing clinical trials. The purpose of this review is to summarize the clinical efficacy and unique toxicities of individually developed CAR-T cell products for the treatment of lymphomas, and their evolution from the laboratory bench to commercialization.

机译：大多数B细胞非霍奇金淋巴瘤（NHL）患者可以用标准的化学免疫疗法治愈。但是，失败的第一线治疗的患者会出现惨淡的结果，尤其是如果他们患有抗挽救疗法的疾病，包括化学免疫疗法，放射线和/或自体干细胞移植。懒惰的B-NHL，例如卵泡淋巴瘤（FL），尽管通常不认为可以治愈多年，但预后良好。然而，一部分懒惰的B-NHL可以将组织学转化为更具侵略性的亚型，其结果类似于侵略性B-NHL。近年来，用嵌合抗原受体进行遗传修饰的T细胞表现出了显着的能力，可诱导化学疗法 - 不良淋巴瘤患者的完全耐用的临床反应。实际上，现在已经批准了两种自体CD19导向的CAR修饰的T细胞产品，用于治疗复发或难治性弥漫性大B细胞淋巴瘤的患者，主要的纵隔B细胞淋巴瘤并转化了FL，而fl则转化了。在正在进行的临床试验中，正在探索其他CAR-T细胞靶标。这篇综述的目的是总结单独开发的CAR-T细胞产品的临床疗效和独特的毒性，以治疗淋巴瘤，以及它们从实验室长凳到商业化的演变。

著录项

来源
《Advances in cell and gene therapy.》 |2019年第3期|e54-e54|共1页
作者
LaQuisa Hill; Premal Lulla; Helen E Heslop;
展开▼
作者单位

The Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类
关键词
Cell Therapy; laboratory bench; LymphomaB-Cell Lymphomasautologous stem cell transplantationoncologyRefractory Diffuse Large B-Cell LymphomaimmunotherapyMacrophage-1 AntigenHodgkin DiseaseAntigen Receptors;

机译：细胞疗法;实验室台;淋巴机 - 细胞淋巴细胞学干细胞移植植入术弥漫性弥漫性大B-细胞淋巴淋巴结式抑制型 - 抗原型抗原型抗原型疾病疾病。;

相似文献

外文文献
中文文献

1. Adu; Aged;; Aged, 80 and over;; Antineoplastic Agents;; Carcinoma, Non-Small-Cell Lung;; Cisplatin;; Cohort Studies;; Deoxycytidine;; Female;; Humans;; Lung Neoplasms;; Male;; Middle Aged;; Mitomycin;; Neoadjuvant Therapy;; Neoplasm Staging;; Pneumonectomy;; Retrospective Studies;; Treatment Outcome;; Vinblastine;; *成年人;; 老年人;; 老年人, 80以上;; 抗肿瘤药;; 癌, 非小细胞肺;; 顺铂;; 队列研究;; 脱氧胞苷;; 肺肿瘤;; 肿瘤辅助疗法;; 肿瘤分期;; 肺切除术;; 回顾性研究;; 治疗结果;; 长春碱 [J] . Clinical cancer research: an official journal of the American Association for Cancer Research . 2009,第18期

机译：Adu; Aged;; Aged, 80 and over;; Antineoplastic Agents;; Carcinoma, Non-Small-Cell Lung;; Cisplatin;; Cohort Studies;; Deoxycytidine;; Female;; Humans;; Lung Neoplasms;; Male;; Middle Aged;; Mitomycin;; Neoadjuvant Therapy;; Neoplasm Staging;; Pneumonectomy;; Retrospective Studies;; Treatment Outcome;; Vinblastine;; *成年人;; 老年人;; 老年人, 80以上;; 抗肿瘤药;; 癌, 非小细胞肺;; 顺铂;; 队列研究;; 脱氧胞苷;; 肺肿瘤;; 肿瘤辅助疗法;; 肿瘤分期;; 肺切除术;; 回顾性研究;; 治疗结果;; 长春碱
2. High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: Early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial [J] . LaurellA., KolstadA., JerkemanM., Leukemia and lymphoma . 2014,第5期

机译：高剂量阿糖胞苷联合利妥昔单抗不足以一线治疗高度增殖的套细胞淋巴瘤：Nordic Lymphoma Group Mantle Cell Lymphoma 5试验的早期结束
3. ALK陰性胃原発anaplastic large cell lymphoma [J] . 小泉和輝, 皆内康一郎, 小谷俊雄, 臨床血液 . 2007,第5期

机译：ALK阴性胃原発anaplastic large cell lymphoma
4. 一种淋巴瘤细胞图像的分割方法（A Segmentation Method for Lymphoma Cell Image） [C] . Chinese Control Conference vol.2; 20040810-13; Wuxi(CN) . 2004

机译：一种淋巴瘤细胞图像的分割方法（A Segmentation Method for Lymphoma Cell Image）
5. Medical History Lifestyle Family History and Occupational Risk Factors for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project [O] . Susan L. Slager, Yolanda Benavente, Aaron Blair, -1

机译：慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的病史生活方式家族史和职业危险因素：InterLymph Non-Hodgkin Lymphoma Subtypes Project
6. Interleukin-10 promoter single nucleotide polymorphism in non-Hodgkin's lymphoma and diffuse large B-cell lymphoma. [O] . 2006

机译：Interleukin-10 promoter single nucleotide polymorphism in non-Hodgkin's lymphoma and diffuse large B-cell lymphoma.

CAR-T cell therapy for non-Hodgkin lymphomas: A new treatment paradigm

摘要

著录项

相似文献

相关主题

期刊订阅